Provided by Tiger Trade Technology Pte. Ltd.

iShares Health Innovation Active ETF

33.32
+0.10420.31%
Post-market: 33.23-0.0850-0.26%16:10 EDT
Volume:583
Turnover:19.40K
Market Cap:13.33M
PE:- -
High:33.32
Open:33.23
Low:33.23
Close:33.21
52wk High:34.86
52wk Low:25.79
Shares:400.00K
Float Shares:400.00K
Volume Ratio:0.29
T/O Rate:0.15%
Dividend:0.08
Dividend Rate:0.24%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Rohto Starts Phase II Trial of RE-01 Cell Therapy for Refractory Ischemic Leg Ulcers

Reuters
·
3 hours ago

Estee Lauder Cos. Cl a Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
10 hours ago

Spectral AI advances DeepView burn diagnostics after FDA nod

TIPRANKS
·
10 hours ago

DataMEDS AI acquires Helomics subsidiary from Axe Compute for $1.5M

TIPRANKS
·
11 hours ago

Health Rounds: New Dye for MRI Exams Detects Lung Cancer Earlier

Reuters
·
12 hours ago

ASX biotech expands diagnostics portfolio after FDA approval

Morning Star AU
·
15 hours ago

Gilead Sciences Expands Lenacapavir Access to 14 Countries

MT Newswires Live
·
Yesterday

As Trump Backs Psychedelics Research, FDA Weighs Safety and Access Standards

Reuters
·
Yesterday

Gilead announces agreement with PAHO for lenacapavir access

TIPRANKS
·
Yesterday

Gilead: Explores Opportunities with Brazilian Health Ministry to Advance Ministry’s Goal of Enabling Local Production of Lenacapavir

THOMSON REUTERS
·
Yesterday

Gilead: Agreement Establishes Regional Pathway Through Pan American Health Organization's Regional Revolving Funds

THOMSON REUTERS
·
Yesterday

Gilead: Co & Paho Announce Partnership to Accelerate Access to Twice-Yearly Lenacapavir for Hiv Prevention Across Latin America & Caribbean

THOMSON REUTERS
·
Yesterday

Gilead, PAHO Agree on HIV Prevention Drug Access in Latin America, Caribbean

Reuters
·
Yesterday

Gilead: to Continue Exploring Opportunities to Work with Paho to Support Country Readiness & Scale-up of Long-Acting Hiv Prevention Access

THOMSON REUTERS
·
Yesterday

Gilead Exec Says Weekly Oral Hiv Prevention Drug Expected to Launch in First Quarter of 2027 - Conf Call

THOMSON REUTERS
·
Yesterday

Gilead Exec Says Hiv Market Growth Should Normalize to 2%-3% Within Next Couple of Quarters - Conf Call

THOMSON REUTERS
·
Yesterday

LIVE Markets-Autumn in New York: Factory Expansion Slows, Input Prices at Multi-Year Highs - Empire State

Reuters
·
Yesterday

LIVE Markets-US Stock Indexes Swing Lower as Oil, Yields Jump

Reuters
·
Yesterday

Johnson & Johnson Says Subcutaneous Cancer Treatment Study Shows Low Rates Across Key Events, Discontinuation

MT Newswires Live
·
Yesterday

Barclays downgrades Scholar Rock on valuation after FDA approval

TIPRANKS
·
Yesterday